阿尔法认知将在阿尔茨海默病协会国际会议上展示ZUNVEYL®（苯甲酸加兰他敏）研究数据Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer’s Association International Conference

动脉网2025-07-08

VANCOUVER, BC and Dallas, TX – July 8 2025, Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing therapies for ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2549473885?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-08 20:34","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2549473885","market":"us","top_or_hot":-1,"title":"阿尔法认知将在阿尔茨海默病协会国际会议上展示ZUNVEYL®（苯甲酸加兰他敏）研究数据Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer’s Association International Conference","media":"动脉网","content":"<div>\n<p>VANCOUVER, BC and Dallas, TX – July 8 2025, Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing therapies for ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708203812979e54ef&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>阿尔法认知将在阿尔茨海默病协会国际会议上展示ZUNVEYL®（苯甲酸加兰他敏）研究数据Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer’s Association International Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n阿尔法认知将在阿尔茨海默病协会国际会议上展示ZUNVEYL®（苯甲酸加兰他敏）研究数据Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer’s Association International Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-08 20:34 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708203812979e54ef&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>VANCOUVER, BC and Dallas, TX – July 8 2025, Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing therapies for ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708203812979e54ef&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708203812979e54ef&s=b","article_id":"2549473885","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708203812979e54ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2549473885","pubTimestamp":1751978040,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"VANCOUVER, BC and Dallas, TX – July 8 2025, Alpha Cognition Inc.  , a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new clinical data on ZUNVEYL at the Alzheimer’s Association International Conference , taking place July 27–31, 2025, in Toronto, Canada.温哥华，不列颠哥伦比亚省和德克萨斯州达拉斯——2025年7月8日，阿尔法认知公司，一家专注于开发神经退行性疾病疗法的商业阶段生物制药公司，今天宣布将在2025年7月27日至31日在加拿大多伦多举行的阿尔茨海默病协会国际会议上展示关于ZUNVEYL的新临床数据。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","ACOG":"ALPHA COGNITION INC","BK4110":"抵押房地产投资信托","AAIC":"阿灵顿资产投资公司"},"translate_title":"Alpha Cognition to Present ZUNVEYL at Alzheimer's Association International Conference ® (Galantamine Benzoate) Study Data Alpha Cognition to Present ZUNVEYL ® (Benzgalantamine) Study Data at Alzheimer's Association International Conference","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AAIC":1,"ACOG":0.9},"content_text":"VANCOUVER, BC and Dallas, TX – July 8 2025, Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new clinical data on ZUNVEYL at the Alzheimer’s Association International Conference (AAIC), taking place July 27–31, 2025, in Toronto, Canada.温哥华，不列颠哥伦比亚省和德克萨斯州达拉斯——2025年7月8日，阿尔法认知公司（纳斯达克股票代码：ACOG）（“阿尔法认知”或“公司”），一家专注于开发神经退行性疾病疗法的商业阶段生物制药公司，今天宣布将在2025年7月27日至31日在加拿大多伦多举行的阿尔茨海默病协会国际会议（AAIC）上展示关于ZUNVEYL的新临床数据。The Company will share the following poster presentations:.公司将分享以下海报展示：。Bioequivalence of ZUNVEYLZUNVEYL的生物等效性, a Galantamine Prodrug to Galantamine Hydrobromide Extended-Release Demonstrated Under，一种加兰他敏前药转化为加兰他敏氢溴酸盐缓释剂型的表现如下Steady State稳态Conditions (Poster #107147) - July 27条件（海报 #107147） - 7月27日Bioequivalence of ZUNVEYLZUNVEYL的生物等效性, a Galantamine Prodrug to Galantamine Hydrobromide Immediate-Release Demonstrated Under，一种加兰他敏前药与盐酸加兰他敏速释制剂的表现Fed and Fasting Conditions (喂养和禁食条件 (Poster#107030) - July 28海报#107030 - 7月28日Dose Proportionality of ZUNVEYLZUNVEYL的剂量比例性, a Galantamine Prodrug, Over a Dosage Range of Five to Fifteen Milligrams Demonstrated Under Fasting Conditions (Poster #107255) -July 30，一种加兰他敏前药，在五到十五毫克的剂量范围内，在空腹条件下展示（海报#107255）- 7月30日“We are excited to present data demonstrating ZUNVEYL’s bioequivalence and dose proportionality,” said Dr. Denis Kay, Chief Scientific Officer of Alpha Cognition. “Given the high unmet need and challenges with current treatments, ZUNVEYL has the potential to offer physicians a well-tolerated therapy with compelling clinical benefits.”.“我们很高兴展示证明ZUNVEYL生物等效性和剂量比例性的数据，”Alpha Cognition首席科学官丹尼斯·凯博士表示。“鉴于目前治疗手段存在的高度未满足需求和挑战，ZUNVEYL有潜力为医生提供一种耐受性良好且具有显著临床益处的疗法。”AAIC is the world’s largest forum for dementia research, convening global leaders in basic and clinical science to advance prevention, diagnosis, and treatment of Alzheimer’s disease.AAIC是全球最大的痴呆研究论坛，汇集了基础科学和临床科学的全球领导者，以推进阿尔茨海默病的预防、诊断和治疗。About Alpha Cognition Inc.关于阿尔法认知公司Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options..阿尔法认知公司是一家商业阶段的生物制药公司，致力于为神经退行性疾病患者开发治疗方法，例如阿尔茨海默病和轻度创伤性脑损伤 (“mTBI”) 引发的认知障碍，目前尚无获批的治疗选择。ALPHA-1062 formulated as a delayed release oral tablet (ZUNVEYL), is an FDA approved new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition.阿尔法-1062制成的缓释口服片剂（ZUNVEYL）是一种FDA批准的新一代乙酰胆碱酯酶抑制剂，用于治疗阿尔茨海默病，预期产生的胃肠道副作用极小。ZUNVEYL的活性代谢物与多奈哌齐和利伐斯的明不同之处在于，它能够结合神经元烟碱受体，尤其是α-7亚型，这种亚型对认知功能有积极影响。ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as a  sublingual formulation for cognitive Impairment with mTBI..ALPHA-1062 还正与美金刚联合开发，用于治疗中度至重度阿尔茨海默病痴呆，并作为舌下含服制剂用于治疗伴有轻度创伤性脑损伤 (mTBI) 的认知障碍。For further information:更多信息请见：Investor Relations投资者关系IR@alphacognition.comIR@alphacognition.comhttps://www.alphacognition.com/https://www.alphacognition.com/INDICATION AND USAGE适应症和用法ZUNVEYL is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults.ZUNVEYL是一种胆碱酯酶抑制剂，用于治疗成人阿尔茨海默型轻度至中度痴呆。IMPORTANT SAFETY INFORMATION重要安全信息CONTRAINDICATIONS禁忌症ZUNVEYL is contraindicated in patients with known hypersensitivity to benzgalantamine, galantamine, or to any inactive ingredients in ZUNVEYL. Serious skin reactions have occurred.对苯扎兰明、加兰他敏或ZUNVEYL中任何非活性成分已知过敏的患者禁用ZUNVEYL。已发生严重皮肤反应。WARNINGS AND PRECAUTIONS警告和注意事项Serious Skin Reactions严重皮肤反应: Serious skin reactions (Stevens-Johnson syndrome and acute generalized exanthematous pustulosis) have been reported in patients receiving galantamine (the active metabolite of ZUNVEYL tablets). If signs or symptoms suggest a serious skin reaction, use of this drug should not be resumed, and alternative therapy should be considered..：接受加兰他敏（ZUNVEYL片的活性代谢物）治疗的患者中已有严重皮肤反应（史蒂文斯-约翰逊综合征和急性泛发性脓疱病）的报告。如果出现提示严重皮肤反应的体征或症状，不应继续使用该药物，并应考虑替代疗法。Anesthesia麻醉: See Drug Interactions Section：参见药物相互作用部分Cardiovascular Conditions:心血管疾病：Cholinesterase inhibitors, including ZUNVEYL, have vagotonic effects on the sinoatrial and atrioventricular nodes, leading to bradycardia and AV block. Bradycardia and all types of heart block have been reported in patients taking cholinesterase inhibitors, both with and without known underlying cardiac conduction abnormalities.胆碱酯酶抑制剂，包括ZUNVEYL，对窦房结和房室结有迷走神经紧张作用，导致心动过缓和房室传导阻滞。据报道，服用胆碱酯酶抑制剂的患者，无论是否已知存在心脏传导异常，均出现心动过缓和各种类型的心脏传导阻滞。Therefore, all patients should be considered at risk for adverse effects on cardiac conduction..因此，所有患者都应被视为对心脏传导有不良影响的风险。Patients treated with galantamine up to 24 mg/day using the recommended dosing schedule showed a dose-related increase in risk of syncope.使用推荐剂量方案，每天服用高达24毫克加兰他敏的患者显示出与剂量相关的晕厥风险增加。Gastrointestinal Conditions胃肠道疾病: Cholinesterase inhibitors, including ZUNVEYL, may increase gastric acid secretion. Patients should be monitored closely for active or occult gastrointestinal bleeding, especially those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). Clinical studies of galantamine have shown no increase, relative to placebo, in the incidence of either peptic ulcer disease or gastrointestinal bleeding..：包括ZUNVEYL在内的胆碱酯酶抑制剂可能会增加胃酸分泌。应密切监测患者是否存在活动性或隐匿性胃肠道出血，特别是那些有溃疡病史或同时接受非甾体抗炎药（NSAIDs）治疗的患者。加兰他敏的临床研究显示，与安慰剂相比，无论是消化性溃疡病还是胃肠道出血的发生率均未增加。Galantamine has been shown to produce nausea, vomiting, diarrhea, anorexia, and weight loss加兰他敏可能会引起恶心、呕吐、腹泻、厌食和体重减轻。.。Monitor the patient's weight during therapy with ZUNVEYL.在使用ZUNVEYL治疗期间，监测患者的体重。Genitourinary Conditions:泌尿生殖系统疾病:Although this was not observed in clinical trials with galantamine, cholinesterase inhibitors, including ZUNVEYL, may cause bladder outflow obstruction.虽然在加兰他敏的临床试验中未观察到这一点，但包括ZUNVEYL在内的胆碱酯酶抑制剂可能会导致膀胱流出道梗阻。Neurological Conditions:神经系统疾病：Cholinesterase inhibitors are believed to have some potential to cause generalized convulsions. Seizure activity may also be a manifestation of Alzheimer's disease. Patients with Alzheimer's disease should be monitored closely for seizures while taking ZUNVEYL.乙酰胆碱酯酶抑制剂被认为有引发全身性抽搐的潜在可能。癫痫发作也可能是阿尔茨海默病的一种表现。服用ZUNVEYL期间，应密切监测阿尔茨海默病患者是否出现癫痫发作。Pulmonary Conditions:肺部疾病：Cholinesterase inhibitors, including ZUNVEYL, should be prescribed with care to patients with a history of severe asthma or obstructive pulmonary disease. Monitor for respiratory adverse reactions.包括ZUNVEYL在内的胆碱酯酶抑制剂，应谨慎开具给有严重哮喘或阻塞性肺病史的患者。监测呼吸系统不良反应。ADVERSE REACTIONS不良反应The most common adverse reactions with galantamine tablets (≥5%) were nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite.加兰他敏片剂最常见的不良反应（≥5%）为恶心、呕吐、腹泻、头晕、头痛和食欲减退。DRUG INTERACTIONS药物相互作用Use with Anticholinergics:与抗胆碱能药物合用：Galantamine has the potential to interfere with the activity of anticholinergic medications.加兰他敏有可能干扰抗胆碱能药物的活性。Use with Cholinomimetics and Other Cholinesterase Inhibitors:与胆碱能药物和其他胆碱酯酶抑制剂合用：A synergistic effect is expected when cholinesterase inhibitors are given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.预计当胆碱酯酶抑制剂与琥珀酰胆碱、其他胆碱酯酶抑制剂、类似的神经肌肉阻断剂或胆碱能激动剂（如贝胆碱）同时给药时，会产生协同效应。USE IN SPECIFIC POPULATIONS特定人群中的使用Pregnancy:怀孕：Based on animal data may cause fetal harm.基于动物数据，可能引起胎儿伤害。Hepatic Impairment:肝功能损害：In patients with moderate hepatic impairment, a decrease in clearance of galantamine was observed; therefore, a dosage adjustment is recommended. Use of ZUNVEYL in patients with severe hepatic impairment is not recommended.在中度肝功能损害患者中，观察到加兰他敏的清除率降低；因此，建议调整剂量。不建议重度肝功能损害患者使用ZUNVEYL。Renal Impairment:肾功能损害:In patients with a creatinine clearance of 9 to 59 mL/min, an increase in exposure of galantamine was observed; therefore, a dosage adjustment is recommended. Use of ZUNVEYL in patients with creatinine clearance less than 9 mL/min is not recommended.在肌酐清除率为 9 至 59 毫升/分钟的患者中，观察到加兰他敏的暴露量增加；因此，建议调整剂量。不建议肌酐清除率低于 9 毫升/分钟的患者使用 ZUNVEYL。These are not all of the possible side effects of ZUNVEYL. You can report side effects to the FDA. Visit这些并非ZUNVEYL的所有可能副作用。您可以向FDA报告副作用。访问www.fda.gov/MedWatchwww.fda.gov/MedWatchor call或打电话1‑800‑FDA‑10881‑800‑食品药品监督管理局‑1088.  Please click here for. 请点击这里以获取Full Prescribing Information完整处方信息.。Forward-looking Statements前瞻性声明This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.本新闻稿包含适用证券法意义上的前瞻性声明。除历史事实陈述外，本新闻稿中包含的任何信息可能为前瞻性声明，反映了公司对未来事件的当前看法，并受已知和未知风险、不确定性、假设及其他可能导致实际结果、活动水平、表现或成就与这些前瞻性声明明示或暗示的信息有重大差异的因素影响。In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future.在某些情况下，您可以通过“可能”、“也许”、“将”、“可以”、“会”、“应该”、“预期”、“打算”、“计划”、“目标”、“预期”、“相信”、“估计”、“预测”、“项目”、“潜力”、“目标”、“寻求”、“考虑”、“继续”和“正在进行”等词语，或这些词语的否定形式，或其他用于识别未来陈述的类似术语来识别前瞻性声明。Forward‐looking statements may include statements regarding the, the long-term benefits of ZUNVEYL, the Company’s timing and planned activities and business strategy to launch ZUNVEYL, the potential timing for the availability of ZUNVEYL, the potential future developments of ZUNVEYL, the market size and demand for ZUNVEYL and the Company’s potential growth opportunities, capital requirements.前瞻性声明可能包括关于ZUNVEYL的长期效益、公司推出ZUNVEYL的时间规划、业务战略、ZUNVEYL可能的上市时间、ZUNVEYL未来的潜在发展、市场规模和需求以及公司的潜在增长机会和资本需求的声明。Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements.  These forward-looking statements are subject to.尽管公司认为每项前瞻性声明都有合理的依据，但我们提醒您，这些声明是基于我们目前已知的事实和因素以及我们对未来的预期，而这些预期并不确定。公司无法保证实际结果将与这些前瞻性声明一致。这些前瞻性声明受制于。www.sedar.comwww.sedar.comand the Company’s filings with the United States Securities and Exchange Commission (the “SEC”), including those risk factors under the heading “Risk Factors” in the Company’s Form S-1/A registration statement as filed with the SEC on January 10, 2025 and available at以及公司向美国证券交易委员会（“SEC”）提交的文件，包括公司于2025年1月10日向SEC提交的S-1/A注册声明中标题为“风险因素”下的那些风险因素，并可访问以下网址获取：www.sec.govwww.sec.gov. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law.这些前瞻性陈述仅截至本新闻稿发布之日，公司没有义务出于任何原因修改或更新任何前瞻性陈述，即使未来有新的信息可用，除非法律要求。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,conferences","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2549473885","isCrawlerRequest":true}